Advanced cardiac fibrosis combined with positive tenascin-C expression was associated with significantly worse event-free survival (P<0.0001) in patients with peripartum cardiomyopathy.
Observational (n=27)
No
Do advanced myocardial fibrosis and Tenascin-C expression predict poor clinical outcomes in patients with peripartum cardiomyopathy?
Advanced myocardial fibrosis and positive Tenascin-C expression on endomyocardial biopsy are significant predictors of poor long-term prognosis in patients with peripartum cardiomyopathy.
p-value: p=<0.0001
Background: Peripartum cardiomyopathy (PPCM) is a potentially life-threatening condition. The histological characteristics of PPCM as risk factors for poor outcomes have not been thoroughly investigated. This study evaluated the pathological findings of PPCM, with a particular focus on inflammatory factors such as tenascin-C (TNC) and interleukin-6, which may predict left ventricular dysfunction and the prognosis of PPCM.
Amemiya et al. (Fri,) conducted a observational in Peripartum cardiomyopathy (n=27). Advanced cardiac fibrosis and Tenascin-C (TNC) expression vs. Mild cardiac fibrosis and TNC negative expression was evaluated on Composite of cardiac death, left ventricular assist device (LVAD) implantation, and/or heart transplantation (p=<0.0001). Advanced cardiac fibrosis combined with positive tenascin-C expression was associated with significantly worse event-free survival (P<0.0001) in patients with peripartum cardiomyopathy.